Tag: immunotherapy

Click to read the study in The Lancet Oncology. Click to see previously reported survival outcomes from the same cohort.
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with cemiplimab monotherapy reported fewer grade 3-4 adverse events.  Evidence Rating Level: 1 (Excellent) Study Rundown: Among patients with advanced non-small-cell lung cancer (NSCLC), a large proportion test positive for programmed cell death...
1. Rituximab was found to significantly reduce median time to remission in new-onset myasthenia gravis. 2. Rituximab appeared to outperform conventional immunosuppressant therapy in terms of need for rescue therapy and adverse effects resulting in discontinuation. Evidence Rating Level: 2 (Good) Myasthenia gravis (MG) is a serious neuromuscular disease, resulting from an autoreactive humoral...
Genetically engineered T-cell therapies, such as chimeric antigen receptor T-cells (CAR T-cells), have been approved for the treatment of hematologic malignancies, however, there are limited data to support this approach in the management of epithelial cancers. Human papillomavirus (HPV)-associated epithelial cancers express viral E6 and E7 oncoproteins, which are...
1. IL-2 is a central cytokine that enhances the immune response, with considerable potential for the treatment of cancer. 2. A mimic of IL-2 binds its receptor more tightly and more potently than the natural cytokine, without adverse effects, in mouse models of melanoma and colon cancer. Evidence Rating Level: 2...